Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLUDROSEPSIS: Fludrocortisone in Septic Shock
NCT05001854Phase 3Suspended
- Sponsor
- CHU Rennes
- Start
- Mar 2022
- Primary completion
- Jun 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in septic shock comparing Fludrocortisone with Placebo (2 arms). Primary endpoint: Mean arterial blood pressure at 7.5 hours. Started Mar 2022; status: suspended.
02
Drugs
fludrocortisone
03
Conditions
septic shock
Beyond the preview
Go deeper on NCT05001854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05001854.